Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Endoscopic and Histological Normalization as a Target to Prevent Clinical Relapse in Ulcerative Colitis Patients.

Scaioli E, Belluzzi A.

Inflamm Bowel Dis. 2018 Nov 21. doi: 10.1093/ibd/izy355. [Epub ahead of print] No abstract available.

PMID:
30462287
2.

Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy.

Sartini A, Scaioli E, Liverani E, Bellanova M, Ricciardiello L, Bazzoli F, Belluzzi A.

Dig Dis Sci. 2018 Oct 17. doi: 10.1007/s10620-018-5329-4. [Epub ahead of print]

PMID:
30334112
3.

Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis.

Scaioli E, Sartini A, Bellanova M, Campieri M, Festi D, Bazzoli F, Belluzzi A.

Clin Gastroenterol Hepatol. 2018 Aug;16(8):1268-1275.e2. doi: 10.1016/j.cgh.2018.01.036. Epub 2018 Jan 31.

PMID:
29391271
4.

The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives.

Scaioli E, Liverani E, Belluzzi A.

Int J Mol Sci. 2017 Dec 5;18(12). pii: E2619. doi: 10.3390/ijms18122619. Review.

5.

Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis.

Prossomariti A, Scaioli E, Piazzi G, Fazio C, Bellanova M, Biagi E, Candela M, Brigidi P, Consolandi C, Balbi T, Chieco P, Munarini A, Pariali M, Minguzzi M, Bazzoli F, Belluzzi A, Ricciardiello L.

Sci Rep. 2017 Aug 7;7(1):7458. doi: 10.1038/s41598-017-07992-1.

6.

Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with Ileal Pouch-Anal Anastomosis for Ulcerative Colitis.

Scaioli E, Sartini A, Liverani E, Digby RJ, Ugolini G, Rosati G, Poggioli G, Festi D, Bazzoli F, Belluzzi A.

Dig Dis Sci. 2017 Apr;62(4):1016-1024. doi: 10.1007/s10620-017-4454-9. Epub 2017 Jan 21.

PMID:
28110377
7.

Is Early Endoscopy-Based Therapy the Best Strategy to Prevent All Crohn's Disease Postoperative Recurrence?

Sartini A, Scaioli E, Belluzzi A.

Gastroenterology. 2016 Nov;151(5):1040-1041. doi: 10.1053/j.gastro.2016.08.058. Epub 2016 Oct 1. No abstract available.

PMID:
27702633
8.

Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease.

Barbara G, Scaioli E, Barbaro MR, Biagi E, Laghi L, Cremon C, Marasco G, Colecchia A, Picone G, Salfi N, Capozzi F, Brigidi P, Festi D.

Gut. 2017 Jul;66(7):1252-1261. doi: 10.1136/gutjnl-2016-312377. Epub 2016 Sep 12.

PMID:
27618836
9.

Different Cutoff Levels of Fecal Calprotectin to Predict Clinical Relapse in Ulcerative Colitis.

Scaioli E, Digby RJ, Belluzzi A.

Inflamm Bowel Dis. 2016 Jul;22(7):E26. doi: 10.1097/MIB.0000000000000839. No abstract available.

PMID:
27271496
10.

MRI Patterns in a Case of 6-Thioguanine-Related Hepatic Sinusoidal Obstruction Syndrome.

Marasco G, Scaioli E, Renzulli M, Colecchia A, Golfieri R, Festi D, Bazzoli F, Digby RJ, Belluzzi A.

Am J Gastroenterol. 2016 Jun;111(6):767. doi: 10.1038/ajg.2016.210. No abstract available.

PMID:
27249976
11.

How to predict clinical relapse in inflammatory bowel disease patients.

Liverani E, Scaioli E, Digby RJ, Bellanova M, Belluzzi A.

World J Gastroenterol. 2016 Jan 21;22(3):1017-33. doi: 10.3748/wjg.v22.i3.1017. Review.

12.

Gut Microbiota and Celiac Disease.

Marasco G, Di Biase AR, Schiumerini R, Eusebi LH, Iughetti L, Ravaioli F, Scaioli E, Colecchia A, Festi D.

Dig Dis Sci. 2016 Jun;61(6):1461-72. doi: 10.1007/s10620-015-4020-2. Epub 2016 Jan 2. Review.

PMID:
26725064
13.

Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon.

Scaioli E, Colecchia A, Marasco G, Schiumerini R, Festi D.

Dig Dis Sci. 2016 Mar;61(3):673-83. doi: 10.1007/s10620-015-3925-0. Epub 2015 Oct 12. Review.

PMID:
26458921
14.

The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid.

Scaioli E, Cardamone C, Liverani E, Munarini A, Hull MA, Belluzzi A.

Biomed Res Int. 2015;2015:360825. doi: 10.1155/2015/360825. Epub 2015 Aug 3.

15.

Clinical application of faecal calprotectin in ulcerative colitis patients.

Scaioli E, Scagliarini M, Cardamone C, Liverani E, Ugolini G, Festi D, Bazzoli F, Belluzzi A.

Eur J Gastroenterol Hepatol. 2015 Dec;27(12):1418-24. doi: 10.1097/MEG.0000000000000461.

PMID:
26308711
16.

Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives.

Festi D, Schiumerini R, Marasco G, Scaioli E, Pasqui F, Colecchia A.

Expert Rev Gastroenterol Hepatol. 2015;9(8):1039-53. doi: 10.1586/17474124.2015.1049155. Epub 2015 May 20. Review.

PMID:
25993881
17.

Can fecal calprotectin better stratify Crohn's disease activity index?

Scaioli E, Cardamone C, Scagliarini M, Zagari RM, Bazzoli F, Belluzzi A.

Ann Gastroenterol. 2015 Apr-Jun;28(2):247-252.

18.

Mycobacterium avium subspecies paratuberculosis in the etiology of Crohn's disease, cause or epiphenomenon?

Liverani E, Scaioli E, Cardamone C, Dal Monte P, Belluzzi A.

World J Gastroenterol. 2014 Sep 28;20(36):13060-70. doi: 10.3748/wjg.v20.i36.13060. Review.

19.

Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: a retrospective multicentre study.

Fuccio L, Correale L, Arezzo A, Repici A, Manes G, Trovato C, Mangiavillano B, Manno M, Cortelezzi CC, Dinelli M, Cennamo V, de Bellis M; KRASTENT Study Group.

Dig Liver Dis. 2014 Jun;46(6):561-7. doi: 10.1016/j.dld.2014.02.006. Epub 2014 Mar 14.

20.

n-3 fatty acids in patients with cardiac risk factors.

Scaioli E, Belluzzi A.

N Engl J Med. 2013 Aug 22;369(8):781. doi: 10.1056/NEJMc1308780. No abstract available.

PMID:
23964945

Supplemental Content

Loading ...
Support Center